CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-28 | Liang Howard CFO & Chief Strategy Officer | Sale | −446 | $365.00 | $163K | 0 |
| 2021-06-18 | Liang Howard CFO & Chief Strategy Officer | Sale | −486 | $325.89 | $158K | 0 |
| 2021-06-07 | Liang Howard CFO & Chief Strategy Officer | Sale | −650 | $354.16 | $230K | 0 |
| 2021-01-15 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +12,600 | $6.50 | $82K | 12,600 |
| 2021-01-15 | Liang Howard CFO & Chief Strategy Officer | Sale | −6,994 | $344.38 | $2.4M | 5,606 |
| 2021-01-15 | Liang Howard CFO & Chief Strategy Officer | Sale | −5,606 | $345.54 | $1.9M | 0 |
| 2021-01-15 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion · Stock Option (Right to Buy) | −163,800 | 649,000 | ||
| 2021-01-14 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +1,400 | $6.50 | $9K | 1,400 |
| 2021-01-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −1,100 | $344.28 | $379K | 300 |
| 2021-01-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −300 | $345.15 | $104K | 0 |
| 2021-01-14 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion · Stock Option (Right to Buy) | −18,200 | 812,800 | ||
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +1,405,300 | $0.50 | $703K | 1,573,715 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +91,900 | $6.50 | $597K | 91,900 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −4,100 | $225.24 | $923K | 87,800 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −6,203 | $226.40 | $1.4M | 81,597 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −15,062 | $227.08 | $3.4M | 66,535 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −7,500 | $227.72 | $1.7M | 59,035 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −400 | $228.10 | $91K | 58,635 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −5,885 | $228.23 | $1.3M | 52,750 |
| 2020-12-14 | Liang Howard CFO & Chief Strategy Officer | Sale | −9,752 | $229.18 | $2.2M | 42,998 |
Page 1 of 5 · 89 trades